Clarifying the enablement standard for pharmaceutical method-of-treatment claims, the US Court of Appeals for the Federal Circuit affirmed a post-verdict grant
In Vitro Data, Broad Dosage Ranges Fail to Enable Patient-Treatment Claims
Source: National Law Review
Read Full Story →
